-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3121 High Grade B-Cell Lymphoma with 11q Aberration Is Not a Rare Event in HIV-Associated LymphomaClinically Relevant Abstract

Program: Oral and Poster Abstracts
Session: 627. Aggressive Lymphomas: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Lymphomas, non-Hodgkin lymphoma, B Cell lymphoma, Diseases, aggressive lymphoma, Lymphoid Malignancies, Biological Processes, pathogenesis
Sunday, December 10, 2023, 6:00 PM-8:00 PM

Amy Chadburn, MD1, Paul Rubinstein, MD2*, Ethel Cesarman, MD, PhD3, Swarna Gogineni4*, MIn Yang5*, Maneeza Bilal, MS6*, Nadine Demko, MD, CM, MSc7*, Ivo N. Sah Bander, MD, PhD7*, Chandler Sy, MD, PhD7*, Victoria Alagiozian-Angelova, MD8* and Liming Bao, MD, PhD9

1Northwestern School Feinberg School of Medicine Northwester Memorial Hospital, New York, NY
2Division of Hematology/Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, IL
3Weill Cornell Medicine, New York
4New York Presbyterian Hospital, New York, NY
5Pathology and Laboratory Medicine, New York Presbyterian Hospital, New York, NY
6Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY
7Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY
8Pathology and Laboratory Medicine, John H. Stroger Hospital of Cook County, Chicago, IL
9Department ot Pathology, Weill Cornell Medicine, New York, NY

High grade B-cell lymphoma with 11q aberration/diffuse large cell lymphoma with 11q aberration (HGBL-11q; previously classified as Burkitt-like lymphoma with 11q aberration, a provisional category in WHO 4-revised) is a relatively new entity recognized by both the WHO-5 and International Consensus Classification (ICC). These lesions show high grade morphology which is often, but not always, similar to Burkitt lymphoma (BL), and a genetic composition that is similar to that of germinal center (GC) derived diffuse large cell lymphoma (DLBCL). While these lymphomas have been described in immunocompetent patients, where they occur usually in children/adolescents and adults under 60 years, they have been only been rarely described in HIV positive patients. In this study we examined the incidence of the 11q aberration in HIV positive lymphomas.

Four tissue microarrays (TMA) containing 144 HIV-associated lymphomas (HIV-NHLs; 57 pre-ART; 16 females; median age 44 years) were examined for the 11q aberration by FISH using the ZytoLight SPEC 11q gain/loss Triple Color Probe (ZytoVision GmbH, Fischai1, Germany). The cases were classified morphologically, evaluated for cell of origin (Hans’ criteria; immunohistochemistry for CD10, BCL6, MUM1), the presence of Kaposi sarcoma herpesvirus (KSHV; immunohistochemistry for LANA) and the Epstein Barr virus (EBV; in situ hybridization; EBER probe). Clinical data, when available, was obtained from the EMR.

Of the 144 cases, 123 (85%) were evaluable by FISH, including 76 DLBCLs, 10 BL, 14 primary effusion lymphoma (PEL)/EC-PEL, 7 plasmablastic lymphomas, 1 marginal zone lymphomas and 15 polymorphic lymphoproliferative lesions. Four abnormal patterns were seen (Table 1) in 39 cases (32%): polysomy ( 3 copies of chromosome 11), 11q23q24 amplification (10 copies), variant or atypical 11q aberration (11q24 loss only) and classic or typical 11q aberration (11q23 gain and 11q24 loss).

Although survival data was available in only a proportion of HIV+ patients with HGBL-11q, these patients showed in general better survival than patients with other chromosome 11 abnormalities (Table 1) and appear to trend to better survivals compared to HIV+ lymphoma patients without the 11q aberration (alive: 11-202 mo; median 73 mo; died 1 – 45 mo; median 6 mo).

Our results demonstrate that chromosome 11 abnormalities are not an uncommon finding in HIV positive lymphoproliferative lesions. Furthermore, although previously only rarely described in HIV+ individuals, HIV-associated lymphomas with the classic or variant 11q aberration is not a rare event. As in immunocompetent patients, the HIV-associated high grade B cell lymphomas with 11q aberration are usually of germinal center origin and EBV negative and in at least some patients are associated with a relatively good prognosis. Thus, these findings indicate that HIV-associated high grade B cell lymphomas with 11q aberration exhibit similar biologic features as those arising in immunocompetent individuals.

Disclosures: Chadburn: Leica Biosystems: Consultancy; Boehringer Ingelheim Pharmaceuticals, Inc.: Consultancy; Medical College of Wisconsin: Honoraria.

*signifies non-member of ASH